In addition, the PPARα agonists gemfibrozil and fenofibrate were able to reduce kidney hypertrophy and fibrosis associated with diabetic nephropathy in two different diabetic animal models [45], [46]. The gene discussed is PPARA; the disease is diabetic kidney disease.